A Prospective Cohort Study Assessing the Efficacy and Safety of Tarceva in 2nd Line in Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Trial Profile

A Prospective Cohort Study Assessing the Efficacy and Safety of Tarceva in 2nd Line in Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2015

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms PEPITA
  • Sponsors Roche
  • Most Recent Events

    • 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer.
    • 14 Oct 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
    • 23 Jun 2014 Planned End Date changed from 1 May 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top